(DARE) Dare Bioscience - Ratings and Ratios

Daré Bioscience, Inc., a biopharmaceutical company, specializes in addressing unmet needs in womens health by identifying, developing, and marketing innovative therapies. The company focuses on contraception, reproductive health, menopause, fertility, and sexual and vaginal health. Its lead product, XACIATO, is approved for the treatment of bacterial vaginosis in females aged 12 and older. Darés pipeline includes Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream for female sexual arousal disorder; DARE-HRT1 for menopausal vasomotor symptoms; DARE-VVA1 for dyspareunia; and DARE-CIN for cervical intraepithelial neoplasia and HPV-related pathologies. Additional pipeline assets include DARE-PDM1 for primary dysmenorrhea, DARE-204 and DARE-214 (injectable etonogestrel contraceptives), DARE-FRT1 (intravaginal ring for IVF support), and DARE-PTB1 for preterm birth prevention. The company is also advancing DARE-LARC1 (levonorgestrel implant), DARE-LBT (vaginal biotherapeutics delivery), DARE-GML (antimicrobial agent), DARE-RH1 (non-hormonal contraception), and DARE-PTB2 (preterm birth treatment via stress protein inhibition). Headquartered in San Diego, California, Daré Bioscience is committed to improving womens health through innovative, patient-centered solutions.

The companys stock (NASDAQ:DARE) is classified under the Health Care Supplies sector. Recent trading data indicates a last price of $2.95, with short-term moving averages (SMA 20 and SMA 50) at $3.09 and $3.18, respectively. The longer-term SMA 200 stands at $3.64, suggesting recent price weakness. The average trading volume over 20 days is 27,769 shares, with an ATR of 0.11, indicating moderate volatility. Fundamental analysis shows a market cap of $26.36M, a P/B ratio of 10.75, and a P/S ratio of 14.01, reflecting a speculative valuation. The ROE of 242.83% highlights significant leverage or operational efficiency.